Cargando…
Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
Liquid biopsy assays for minimal residual disease (MRD) are used to monitor and inform oncological treatment and predict the risk of relapse in cancer patients. To-date, most MRD assay development has focused on targeting somatic mutations. However, epigenetic changes are more frequent and universal...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110851/ https://www.ncbi.nlm.nih.gov/pubmed/37081990 http://dx.doi.org/10.3389/fonc.2023.1103797 |
_version_ | 1785027330228355072 |
---|---|
author | Johnston, Andrew D. Ross, Jason P. Ma, Chenkai Fung, Kim Y. C. Locke, Warwick J. |
author_facet | Johnston, Andrew D. Ross, Jason P. Ma, Chenkai Fung, Kim Y. C. Locke, Warwick J. |
author_sort | Johnston, Andrew D. |
collection | PubMed |
description | Liquid biopsy assays for minimal residual disease (MRD) are used to monitor and inform oncological treatment and predict the risk of relapse in cancer patients. To-date, most MRD assay development has focused on targeting somatic mutations. However, epigenetic changes are more frequent and universal than genetic alterations in cancer and circulating tumor DNA (ctDNA) retains much of these changes. Here, we review the epigenetic signals that can be used to detect MRD, including DNA methylation alterations and fragmentation patterns that differentiate ctDNA from noncancerous circulating cell-free DNA (ccfDNA). We then summarize the current state of MRD monitoring; highlight the advantages of epigenetics over genetics-based approaches; and discuss the emerging paradigm of assaying both genetic and epigenetic targets to monitor treatment response, detect disease recurrence, and inform adjuvant therapy. |
format | Online Article Text |
id | pubmed-10110851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101108512023-04-19 Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? Johnston, Andrew D. Ross, Jason P. Ma, Chenkai Fung, Kim Y. C. Locke, Warwick J. Front Oncol Oncology Liquid biopsy assays for minimal residual disease (MRD) are used to monitor and inform oncological treatment and predict the risk of relapse in cancer patients. To-date, most MRD assay development has focused on targeting somatic mutations. However, epigenetic changes are more frequent and universal than genetic alterations in cancer and circulating tumor DNA (ctDNA) retains much of these changes. Here, we review the epigenetic signals that can be used to detect MRD, including DNA methylation alterations and fragmentation patterns that differentiate ctDNA from noncancerous circulating cell-free DNA (ccfDNA). We then summarize the current state of MRD monitoring; highlight the advantages of epigenetics over genetics-based approaches; and discuss the emerging paradigm of assaying both genetic and epigenetic targets to monitor treatment response, detect disease recurrence, and inform adjuvant therapy. Frontiers Media S.A. 2023-04-04 /pmc/articles/PMC10110851/ /pubmed/37081990 http://dx.doi.org/10.3389/fonc.2023.1103797 Text en Copyright © 2023 Johnston, Ross, Ma, Fung and Locke https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Johnston, Andrew D. Ross, Jason P. Ma, Chenkai Fung, Kim Y. C. Locke, Warwick J. Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title | Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title_full | Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title_fullStr | Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title_full_unstemmed | Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title_short | Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
title_sort | epigenetic liquid biopsies for minimal residual disease, what’s around the corner? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110851/ https://www.ncbi.nlm.nih.gov/pubmed/37081990 http://dx.doi.org/10.3389/fonc.2023.1103797 |
work_keys_str_mv | AT johnstonandrewd epigeneticliquidbiopsiesforminimalresidualdiseasewhatsaroundthecorner AT rossjasonp epigeneticliquidbiopsiesforminimalresidualdiseasewhatsaroundthecorner AT machenkai epigeneticliquidbiopsiesforminimalresidualdiseasewhatsaroundthecorner AT fungkimyc epigeneticliquidbiopsiesforminimalresidualdiseasewhatsaroundthecorner AT lockewarwickj epigeneticliquidbiopsiesforminimalresidualdiseasewhatsaroundthecorner |